Burkitt's lymphoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
Kamal Akbar (talk | contribs) No edit summary |
Kamal Akbar (talk | contribs) No edit summary |
||
| Line 15: | Line 15: | ||
* There is a high risk that Burkitt's lymphoma will spread to the central nervous system ([[CNS]]) | * There is a high risk that Burkitt's lymphoma will spread to the central nervous system ([[CNS]]) | ||
* CNS prophylaxis may involve giving [[intrathecal]] chemotherapy, high doses of systemic therapy, or both methods may be used | * CNS prophylaxis may involve giving [[intrathecal]] chemotherapy, high doses of systemic therapy, or both methods may be used | ||
* [[Methotrexate]] and [[Cytarabine]] are the drugs used most often for CNS prophylaxis | * [[Methotrexate]] and [[Cytarabine]] are the drugs used most often for CNS prophylaxis<ref name="pmid27846613">{{cite journal| author=Peñalver FJ, Sancho JM, de la Fuente A, Olave MT, Martín A, Panizo C et al.| title=Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). | journal=Haematologica | year= 2017 | volume= 102 | issue= 2 | pages= 235-245 | pmid=27846613 | doi=10.3324/haematol.2016.149120 | pmc=5286932 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27846613 }} </ref> | ||
===Biological therapy=== | ===Biological therapy=== | ||
* [[Monoclonal antibodies]] are a type of biological therapy that is effective in treating Burkitt's lymphoma | * [[Monoclonal antibodies]] are a type of biological therapy that is effective in treating Burkitt's lymphoma | ||
Revision as of 21:53, 8 January 2019
|
Burkitt's lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Burkitt's lymphoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Burkitt's lymphoma medical therapy |
|
Risk calculators and risk factors for Burkitt's lymphoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
The predominant therapy for Burkitt's lymphoma is chemotherapy. Adjunctive immunotherapy and stem cell transplantation may be required.
Medical Therapy
The predominant therapy for Burkitt's lymphoma is chemotherapy. Adjunctive immunotherapy and stem cell transplantation may be required.[1]
Chemotherapy
- Chemotherapeutic regimens for Burkitt's lymphoma include:[2]
- Cyclophosphamide AND Vincristine AND Doxorubicin AND Methotrexate (CODOX-M)[3]
- Ifosfamide AND Mesna AND Etoposide AND Cytarabine (IVAC)
- Cyclophosphamide AND Vincristine AND Doxorubicin AND Dexamethasone AND Methotrexate AND Cytarabine (Hyper-CVAD)
CNS prophylaxis
- There is a high risk that Burkitt's lymphoma will spread to the central nervous system (CNS)
- CNS prophylaxis may involve giving intrathecal chemotherapy, high doses of systemic therapy, or both methods may be used
- Methotrexate and Cytarabine are the drugs used most often for CNS prophylaxis[4]
Biological therapy
- Monoclonal antibodies are a type of biological therapy that is effective in treating Burkitt's lymphoma
- Rituximab may be added to each of the above chemotherapy regimens[2]
Stem cell transplant
- A stem cell transplant may be offered to patients with recurrent Burkitt's lymphoma or to patients who relapse after the treatment.[2]
References
- ↑ Burkitt lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/burkitt-lymphoma/?region=on Accessed on September 28, 2015
- ↑ 2.0 2.1 2.2 Jacobson, C.; LaCasce, A. (2014). "How I treat Burkitt lymphoma in adults". Blood. 124 (19): 2913–2920. doi:10.1182/blood-2014-06-538504. ISSN 0006-4971.
- ↑ Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K; et al. (2018). "Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab". Br J Haematol. 181 (6): 782–790. doi:10.1111/bjh.15262. PMID 29741758.
- ↑ Peñalver FJ, Sancho JM, de la Fuente A, Olave MT, Martín A, Panizo C; et al. (2017). "Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)". Haematologica. 102 (2): 235–245. doi:10.3324/haematol.2016.149120. PMC 5286932. PMID 27846613.